Kura Oncology, Inc.
KURAKura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for the treatment of cancer. The company's pipeline primarily includes small-molecule drugs designed to selectively inhibit specific proteins involved in cancer growth and progression. Based in San Diego, California, Kura aims to address unmet medical needs in oncology with precision medicines.
Company News
Multiple biotech companies are advancing innovative immunotherapy and targeted treatments for blood cancers, with significant clinical trial progress and FDA approvals in acute myeloid leukemia (AML) and related hematologic conditions.
Kura Oncology and Kyowa Kirin announced FDA approval of KOMZIFTI, a once-daily oral menin inhibitor for relapsed/refractory NPM1-mutated AML, which has been added to NCCN Guidelines as a recommended treatment option.
These two healthcare growth stocks could have a lot more room to run.
Mirati (MRTX) posts mixed third-quarter results as the bottom line exceeds estimates while the top line misses.
